How academic labs can approach the drug discovery process as a way to synergize with big pharma

Arianna Loregian; Giorgio Palù

doi:10.1016/j.tim.2013.03.006

How academic labs can approach the drug discovery process as a way to synergize with big pharma

Trends Microbiol. 2013 Jun;21(6):261-4. doi: 10.1016/j.tim.2013.03.006.

Authors

Arianna Loregian¹, Giorgio Palù

Affiliation

¹ Department of Molecular Medicine, University of Padua, Padua, Italy. arianna.loregian@unipd.it

PMID: 23731493
DOI: 10.1016/j.tim.2013.03.006

Abstract

While the pharmaceutical industry is facing highly challenging times, the academic drug discovery sector has the potential to contribute meaningfully to the discovery of novel drug targets and to the development of new mode-of-action therapeutics against a range of diseases, including rare and neglected diseases.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Academic Medical Centers / organization & administration*
Biomedical Research
Drug Discovery*
Drug Industry / organization & administration*
Humans
Public-Private Sector Partnerships*
Universities / organization & administration*